Recombinant artificial lectins with oligomannose glycan specificity

Recombinant oligomannose binding lectins, such as BALMS, address the challenge of selectively purifying antibodies and targeting high-mannose glycans associated with cancer and viral infections, achieving efficient binding and therapeutic efficacy.

WO2025064363A1 Publication Date: 2025-03-27EMORY UNIVERSITY
5 Cites 0 Cited by

Patent Information

Application Number
PCT/US2024/046980
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-05-17
Filing Date
2024-09-16
Publication Date
2025-03-27

AI Technical Summary

Technical Problem

Current technologies lack efficient methods for selectively purifying antibodies with desired N-glycosylation properties and targeting aberrant high-mannose glycans associated with cancer and viral infections.

Method used

Development of recombinant oligomannose binding lectins, such as Bacteroides Artificial Lectins with High-Mannose Specificity (BALMS), which are engineered to have high-specificity and high-affinity binding to high-mannose N-glycans, allowing for selective purification of antibodies and targeting of cancer and viral cells.

Benefits of technology

BALMS effectively bind to high-mannose N-glycans with low nanomolar affinity, enabling efficient purification of antibodies and targeted therapy for cancer and viral infections by disrupting the tumor microenvironment and neutralizing viruses.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

This disclosure contemplates recombinant oligomannose binding lectins reported herein. In certain embodiments, this disclosure contemplates uses of recombinant oligomannose binding lectins disclosed herein for purification and detection methods. In certain embodiments, this disclosure contemplates uses of recombinant oligomannose binding lectins disclosed herein for treating or preventing viral infections, cancer, or other immunological diseases or conditions. In certain embodiments, this disclosure relates to pharmaceutical compositions comprising recombinant oligomannose binding lectins disclosed herein or nucleic acid or vector encoding the same.
Need to check novelty before this filing date? Find Prior Art